Scarica l'app Stockscreener
10.52
3.85%
0.39
Dopo l'orario di chiusura:
10.62
0.10
+0.95%
Precedente Chiudi:
$10.13
Aprire:
$10.72
Volume 24 ore:
6.71M
Relative Volume:
0.99
Capitalizzazione di mercato:
$1.22B
Reddito:
$52.86M
Utile/perdita netta:
$-480.19M
Rapporto P/E:
-2.2431
EPS:
-4.6899
Flusso di cassa netto:
$-421.82M
1 W Prestazione:
+17.02%
1M Prestazione:
+11.44%
6M Prestazione:
-5.40%
1 anno Prestazione:
-12.48%
Intervallo 1D:
$10.32
$10.74
Intervallo di 1 settimana:
$9.05
$10.74
Portata 52W:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Confronta NTLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
10.52 | 1.17B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Why Intellia Therapeutics Inc. (38I) stock fits value portfolios2025 Key Lessons & Risk Managed Investment Signals - ulpravda.ru
Is Intellia Therapeutics Inc. stock a defensive play in 2025Wall Street Watch & Safe Capital Allocation Plans - ulpravda.ru
How Intellia Therapeutics Inc. stock benefits from global expansion2025 Earnings Surprises & Safe Swing Trade Setups - ulpravda.ru
Buyback Watch: Can Intellia Therapeutics Inc. stock beat market expectations this quarterWeekly Trend Report & Free Long-Term Investment Growth Plans - ulpravda.ru
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Insider Buying: Fred Cohen Acquires 150,000 Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus
Intellia Therapeutics Insider Sold Shares Worth $314,485, According to a Recent SEC Filing - MarketScreener
Intellia Therapeutics prepares for JPM Healthcare Conference presentation - Traders Union
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics
Gene editing firm Intellia to share CRISPR work at major health event - Stock Titan
What analysts say about Intellia Therapeutics Inc 38I stockUtilities Sector Analysis & Identify Ideal Buy Points With Precision - earlytimes.in
BofA Adjusts Price Target on Intellia Therapeutics to $12 From $14, Maintains Neutral Rating - MarketScreener
Intellia Stock Declines Around 55% in 3 Months: Here's Why - Finviz
Intellia Therapeutics reports inducement grants - Medical Buyer
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully - Yahoo Finance
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aug Big Picture: Can Intellia Therapeutics Inc stock beat analyst upgradesJuly 2025 Momentum & Daily Technical Stock Forecast Reports - moha.gov.vn
Trading the Move, Not the Narrative: (NTLA) Edition - Stock Traders Daily
Short Squeeze: Is Intellia Therapeutics Inc stock a defensive play in 20252025 Support & Resistance & Real-Time Chart Breakout Alerts - moha.gov.vn
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga
Cathie Wood shells out $1.3 million on biotech stock - Yahoo Finance
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab - Yahoo Finance
Cathie Wood’s ARK makes strategic stock moves, buys Intellia and sells Roku By Investing.com - Investing.com South Africa
Cathie Wood’s ARK makes strategic stock moves, buys Intellia and sells Roku - Investing.com
What makes Intellia Therapeutics (NTLA) an interesting investment? - MSN
What Makes Intellia Therapeutics (NTLA) an Interesting Investment? - Finviz
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street - Finviz
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN
Voya Investment Management LLC Trims Stock Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Intellia Therapeutics (NASDAQ:NTLA) Cut to "Sell" at Wall Street Zen - MarketBeat
Is Intellia Therapeutics Inc 38I a good long term investmentExit Strategy Tips & Download Our Free Trading Blueprint - earlytimes.in
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Will Intellia Therapeutics Inc. stock remain a Wall Street favoriteTrade Ideas & Long-Term Growth Plans - ulpravda.ru
Intellia Therapeutics Earnings Notes - Trefis
Will Intellia Therapeutics Inc. stock continue dividend increasesJuly 2025 Momentum & Stepwise Trade Signal Implementation - DonanımHaber
Will Intellia Therapeutics Inc. (38I) stock hit analyst forecastsJuly 2025 Retail & Weekly High Momentum Picks - DonanımHaber
Is Intellia Therapeutics Inc. stock a top momentum play2025 Stock Rankings & Accurate Buy Signal Alerts - DonanımHaber
Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring a 152.61% Potential Upside in Gene Editing Revolution - DirectorsTalk Interviews
Will Intellia Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Analyst Calls & Growth Focused Stock Pick Reports - Улправда
Intellia Therapeutics (NTLA) Receives a Buy from Leerink Partners - The Globe and Mail
Intellia Therapeutics (NTLA) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
623,600 Shares in Intellia Therapeutics, Inc. $NTLA Acquired by Marex Group plc - MarketBeat
Intellia Therapeutics, Inc. $NTLA Shares Sold by Nikko Asset Management Americas Inc. - MarketBeat
Intellia Therapeutics CEO Sells Shares Under Trading Plan - TradingView — Track All Markets
Intellia Therapeutics, Inc. $NTLA Shares Purchased by Armistice Capital LLC - MarketBeat
(NTLA) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
JPMorgan Chase & Co. Purchases 396,858 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):